Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison

Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison

Aim: Despite the availability of novel treatment options for patients with triple-class exposed/refractory multiplemyeloma , there is a lack of consensus on the optimal regimen. A previous unanchored matchingadjusted indirect comparison (MAIC) of the MagnetisMM-3 (NCT04649359) and LocoMMotion (NCT...

Full description

Saved in:
Bibliographic Details
Main Authors: Isha Mol, Yannan Hu, Thomas W LeBlanc, Joseph C Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Isabel Perez Cruz, Patrick Hlavacek
Format: Article
Language:English
Published: Becaris Publishing Limited 2025-04-01
Series:Journal of Comparative Effectiveness Research
Subjects:
elranatamab
locommotion
magnetismm-3
matching-adjusted indirect comparison
physician’s choice of treatment
triple-class exposed/refractory multiple myeloma
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items